Insider Selling: SBC Medical Group (NASDAQ:SBC) CEO Sells 465,000 Shares of Stock

Key Points

• CEO Yoshiyuki Aikawa has been selling stock: he disposed of 7,987,900 shares across March 6, April 21 and April 28 for roughly $20.14 million (including 465,000 shares on April 28 at $3.02), and still holds 78,839,460 shares—this latest sale cut his ownership by about 0.59%.
• The stock trades near $3.30 after reporting quarterly EPS of $0.14 (beating estimates) but revenue of $39.57M (below estimates); SBC has a $338.5M market cap, a PE of 6.73, and a consensus analyst rating of Hold with an $8.50 price target.

SBC Medical Group Holdings Incorporated (NASDAQ:SBC - Get Free Report) CEO Yoshiyuki Aikawa sold 465,000 shares of the business's stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $3.02, for a total transaction of $1,404,300.00. Following the transaction, the chief executive officer owned 78,839,460 shares in the company, valued at approximately $238,095,169.20. This trade represents a 0.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Yoshiyuki Aikawa also recently made the following trade(s):

• On Tuesday, April 21st, Yoshiyuki Aikawa sold 3,100,000 shares of SBC Medical Group stock. The stock was sold at an average price of $3.02, for a total transaction of $9,362,000.00.
• On Friday, March 6th, Yoshiyuki Aikawa sold 4,422,900 shares of SBC Medical Group stock. The stock was sold at an average price of $2.12, for a total transaction of $9,376,548.00.

SBC Medical Group Stock Performance

Shares of SBC Medical Group stock traded down $0.08 on Wednesday, reaching $3.30. 226,419 shares of the stock were exchanged, compared to its average volume of 59,752. SBC Medical Group Holdings Incorporated has a 1-year low of $2.97 and a 1-year high of $5.75. The company has a current ratio of 3.78, a quick ratio of 3.74 and a debt-to-equity ratio of 0.13. The business has a fifty day moving average price of $3.91 and a two-hundred day moving average price of $3.99. The firm has a market capitalization of $338.50 million, a PE ratio of 6.73 and a beta of 0.99.

SBC Medical Group (NASDAQ:SBC - Get Free Report) last issued its quarterly earnings results on Friday, March 27th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.13 by $0.01. SBC Medical Group had a net margin of 29.37% and a return on equity of 20.76%. The business had revenue of $39.57 million for the quarter, compared to analyst estimates of $45.19 million. As a group, research analysts anticipate that SBC Medical Group Holdings Incorporated will post 0.47 earnings per share for the current fiscal year.

Hedge Funds Weigh In On SBC Medical Group

Institutional investors and hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. acquired a new position in SBC Medical Group during the fourth quarter worth approximately $49,000. Russell Investments Group Ltd. increased its position in SBC Medical Group by 292.0% during the fourth quarter. Russell Investments Group Ltd. now owns 11,775 shares of the company's stock worth $51,000 after purchasing an additional 8,771 shares during the last quarter. Nuveen LLC acquired a new position in SBC Medical Group during the fourth quarter worth approximately $53,000. Wells Fargo & Company MN increased its position in SBC Medical Group by 195.1% during the fourth quarter. Wells Fargo & Company MN now owns 12,626 shares of the company's stock worth $54,000 after purchasing an additional 8,348 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of SBC Medical Group in the second quarter worth $64,000. Institutional investors and hedge funds own 60.82% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently commented on SBC shares. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of SBC Medical Group in a report on Friday, March 27th. BTIG Research started coverage on shares of SBC Medical Group in a report on Friday, March 6th. They issued a "buy" rating and a $8.00 price target on the stock. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, SBC Medical Group has an average rating of "Hold" and a consensus price target of $8.50.

SBC Medical Group Company Profile

SBC Medical Group, Inc is a publicly traded healthcare management services company listed on the Nasdaq under the ticker SBC. The company specializes in supporting in-office ancillary service providers by offering a suite of administrative and operational solutions designed to streamline practice management and enhance revenue performance. Its core mission is to help physician practices, imaging centers and other ancillary service providers focus on patient care while outsourcing complex back-office functions.

The company's primary offerings include revenue cycle management, medical billing and coding, compliance oversight and transcription services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.